Clinical trials: Neuroprotective
Glaucoma, Open-Angle
Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma
This is a randomized, double blind study with competitive enrolment, aimed to enroll a total of 70 patients with a diagnosis of primary open angle glaucoma (POAG).
- Trial name
- NCT04038034
- Testing
- CoQ10- MINIACTIVES
- Where
- 2 sites in Italy
- Volunteers
- 70 people
- Sponsor
- VISUfarma SpA
Ischemic Stroke
Oriental Research AlliaNce of Acute Ischemic Stroke Given Endovascular Treatment
To determine the safety and efficacy of in situ ischemic postconditioning immediately after successful reperfusion in AIS patients underwnet EVT.
- Trial name
- ORANGE (NCT05024292)
- Testing
- rapid local ischemic postconditioning (RL-IPostC)
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Retinal Detachment
Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery
This study is indicated for patients with extended rhegmatogenous retinal detachment (RRD) (≥ 2 quadrants) with macula OFF lasting 7 days or less, pseudophakic or aphakic, and scheduled to undergo surgical intervention with…
- Trial name
- UDCA (NCT06294847)
- Testing
- Ursolvan
- Where
- 2 sites in France
- Volunteers
- 120 people
- Sponsor
- Hopital Foch
Stroke, Acute, Ischemic
Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT
Background: Stroke is the third major cause of death and disability worldwide. It was shown that combining early reperfusion therapy (thrombolysis and/or thrombectomy) with stroke unit care and immediate rehabilitation have…
- Trial name
- NCT05124353
- Testing
- Cerebrolysin
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Pomeranian Medical University Szczecin
Amyotrophic Lateral Sclerosis
Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis
The preclinical rationale for tauroursodeoxycholic acid (TUDCA) use in treating patients with amyotrophic lateral sclerosis (ALS) stems from the demonstration of antioxidant, antiapoptotic and neuroprotective properties of TUDCA…
- Trial name
- TUDCA-ALS (NCT00877604)
- Testing
- tauroursodeoxycholic acid (TUDCA)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Premature Birth, NEUROPROTECTION
Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries
A Cochrane systematic review has confirmed that fetal exposure to magnesium sulphate given before preterm birth has a neuroprotective role.
- Conditions
- Premature Birth, NEUROPROTECTION, MAGNESIUM SULPHATE, Cerebral Palsy
- Trial name
- NCT05674565
- Testing
- Magnesium sulfate loading with maintenance dose, Magnesium sulfate loading dose only
- Where
- Egypt
- Volunteers
- 336 people
- Sponsor
- Zagazig University
Amyotrophic Lateral Sclerosis, ALS
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Phase 1, open-label study of BHV-0223 in ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease
- Trial name
- NCT03520517
- Testing
- BHV-0223
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Multiple Sclerosis, Relapsing-Remitting
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
Alemtuzumab is the active agent of a drug called Lemtrada®. In the European Union, Lemtrada® is approved for the treatment of a particular form of multiple sclerosis (the so called relapsing remitting form).
- Trial name
- ALAIN01 (NCT02419378)
- Testing
- Alemtuzumab
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital Muenster
Ischemic Stroke
Improving Neuroprotective Strategy for Ischemic Stroke After Thrombectomy Followed by DELP (INSIST-DELP)
Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) has been found to improve neurological function and life ability of AIS patients and approved for the treatment of AIS by China Food and Drug Administration (CFDA).
- Trial name
- NCT04708730
- Testing
- Delipid Extracorporeal Lipoprotein filter from Plasma
- Where
- China
- Volunteers
- 60 people
- Sponsor
- General Hospital of Shenyang Military Region
Peripheral Nerve Disease
Neuroprotection of Memantine and Rosuvastatin
Memantine is used to slow the neurotoxicity of Alzheimer disease. Rosuvastatin used as a lipid-lowering agent . Increased bioavailability of endothelial-derived nitric oxide improves endothelium function , increases cerebral…
- Trial name
- NCT07504198
- Testing
- Memantine, Rosuvastatin 20 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Tanta University
Parkinson Disease
Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease
Background: Recent evidence has shown that statins, especially lipophilic statins, may have a neuroprotective benefit in Parkinson's disease (PD).
- Trial name
- NCT03242499
- Testing
- Lovastatin
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Optic Neuropathy, Glaucoma
Hyperbaric Oxygen Therapy for Optic Neuropathies
The purpose of the study is to evaluate the neuroprotective efficacy of hyperbaric oxygen for the treatment in patients with optic neuropathy.
- Trial name
- HBOT (NCT06128720)
- Testing
- Hyperbaric Oxygen
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Stanford University
Cognitive Disorders, HIV Infections
A Study of Decreased Mental Function Associated With HIV
The purpose of this study is to compare pictures of the brain of HIV-infected people with memory problems before and after treatment with selegiline. Selegiline is the study drug received through A5090.
- Trial name
- NCT00027040
- Testing
- Selegiline hydrochloride
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes
The purpose of this research is to determine if patients who receive phenytoin (also commonly known as Dilantin) before taking corticosteroids will show less memory impairment and hypomanic symptoms (feelings of agitation…
- Trial name
- NCT00591006
- Testing
- Phenytoin (brand name Dilantin), Hydrocortisone
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Parkinson's Disease
Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease
GM608 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system.
- Trial name
- GAP-PD (NCT01850381)
- Testing
- GM608
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Genervon Biopharmaceuticals, LLC
Intracerebral Hemorrhage
A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage
Intracerebral hemorrhage (ICH) is a devastating form of cerebrovascular disease for which there are no approved therapeutics that improve outcomes.
- Trial name
- NCT06255977
- Testing
- CN-105
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Beijing Tiantan Hospital
Heart Defects, Congenital
Neuroprotective Effects of Remote Ischemic Preconditioning (RIPC) During Infant Cardiac Surgery
The purpose of this study is to look at whether the use of a simple technique before surgery, which involves inflating a blood pressure cuff on the infant's leg, can improve development of language, motor and thinking skills at…
- Trial name
- NCT01835392
- Testing
- Remote Ischemic Preconditioning, Control
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Nemours Children's Clinic
Multiple Sclerosis, Chronic Progressive
Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis.
- Trial name
- NCT01188811
- Testing
- lipoic acid
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- VA Office of Research and Development
Stroke, Acute
Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke
The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients.
- Trial name
- MINOS (NCT00630396)
- Testing
- Minocycline
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- David Hess, MD
Older People
Study of the Cognitive and Neurophysiological Effects of the Activ4Brain Program for Older Adults
This study aims to examine the cognitive, neuronal, and physical effects of the Activ4Brain program in older men and women between 55 and 75 years of age.
- Trial name
- Activ4Brain (NCT07108413)
- Testing
- Activ4Brain Program, Aerobic Exercise Program
- Where
- Portugal
- Volunteers
- 72 people
- Sponsor
- University of Coimbra